07:10 AM EDT, 09/18/2024 (MT Newswires) -- MannKind ( MNKD ) said Wednesday it received clearance from Japan's Pharmaceuticals and Medical Devices Agency to begin the phase 3 trial of its Clofazimine Inhalation Suspension treatment for lung disease.

The study is now cleared in four countries including Japan, MannKind ( MNKD ) said, adding that it expects approval from Taiwan in Q4.

Price: 6.70, Change: +0.14, Percent Change: +2.13